Myriad Genetics is handing Labcorp a $210 million piece of the prenatal testing market, turning a portfolio reshuffle into a fresh sign of how genetic diagnostics are being consolidated. For Myriad, the transaction marks a move away from one part of its business. For Labcorp, it offers a broader position in prenatal genetic testing.

The agreement puts two distinct strategies on the same transaction docket: Myriad is streamlining its portfolio, while Labcorp is expanding its prenatal testing footprint. In a sector where capabilities and scale matter, the deal shows how one company’s divestiture can become another’s growth platform.

Myriad Genetics ($MYGN) agreed to sell its prenatal health testing business to Labcorp ($LH) for $210 million, according to the reported transaction. The price is the clearest hard number attached to the deal—and the most useful marker of the strategic handoff.

A sharper portfolio for Myriad

A divestiture is more than a line item changing hands. It redraws the company’s business map. By selling its prenatal health testing business, Myriad is reshaping its focus going forward and narrowing the portfolio it will operate after the transaction.

The announcement does not provide details on how Myriad would use the proceeds, nor does it specify valuation multiples, closing conditions or the potential effect on shareholders. Those omissions matter: the strategic rationale is visible, but the financial afterstory remains outside the information provided.

Still, the direction is straightforward. Myriad’s role in this transaction is that of a company simplifying its portfolio through a $210 million divestiture. That can make the corporate story easier to read, even if the deal itself does not answer every question about the company’s next chapter.

Labcorp adds another prenatal piece

For Labcorp, the same transaction points in the opposite direction. The company is expanding its footprint in prenatal genetic testing, adding the business Myriad is selling. That gives Labcorp a larger presence in a specialized diagnostics area without requiring the market to guess at the deal’s central strategic logic.

The transaction therefore has a tidy symmetry: Myriad is reducing the breadth of its portfolio, while Labcorp is increasing its reach in prenatal testing. Whether that produces broader benefits for either company will depend on information not included in the announcement, but the immediate strategic contrast is clear.

Another marker of diagnostics consolidation

The deal also fits the broader pattern of continued consolidation in genetic testing and diagnostics. Businesses are being repositioned as companies decide where they want to concentrate their capabilities and where another operator may have a stronger strategic fit.

That makes this more than a $210 million exchange between $MYGN and $LH. It is a small but visible example of a market being assembled and reassembled around focused portfolios and expanded testing footprints. Myriad’s prenatal business is leaving one platform and joining another, while the sector’s competitive landscape continues to take shape through transactions like this one.

For investors watching the diagnostics space, the headline is simple: Myriad is streamlining, and Labcorp is building out. The harder questions—about execution, proceeds and shareholder consequences—remain unanswered by the available details.